JP2025134707A5 - - Google Patents
Info
- Publication number
- JP2025134707A5 JP2025134707A5 JP2025085673A JP2025085673A JP2025134707A5 JP 2025134707 A5 JP2025134707 A5 JP 2025134707A5 JP 2025085673 A JP2025085673 A JP 2025085673A JP 2025085673 A JP2025085673 A JP 2025085673A JP 2025134707 A5 JP2025134707 A5 JP 2025134707A5
- Authority
- JP
- Japan
- Prior art keywords
- δ1γδt
- cells
- sequence
- cell
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739822P | 2018-10-01 | 2018-10-01 | |
| US62/739,822 | 2018-10-01 | ||
| JP2021542089A JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| PCT/US2019/054132 WO2020072536A1 (en) | 2018-10-01 | 2019-10-01 | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Division JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025134707A JP2025134707A (ja) | 2025-09-17 |
| JP2025134707A5 true JP2025134707A5 (enExample) | 2026-04-01 |
Family
ID=68393055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210388100A1 (enExample) |
| EP (1) | EP3860645A1 (enExample) |
| JP (2) | JP7687952B2 (enExample) |
| KR (1) | KR20210070330A (enExample) |
| CN (1) | CN113056283A (enExample) |
| AU (1) | AU2019354391A1 (enExample) |
| BR (1) | BR112021006182A2 (enExample) |
| CA (1) | CA3115139A1 (enExample) |
| EA (1) | EA202190926A1 (enExample) |
| IL (1) | IL281922A (enExample) |
| MX (1) | MX2021003745A (enExample) |
| SG (1) | SG11202103235PA (enExample) |
| WO (1) | WO2020072536A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP4004049A1 (en) * | 2019-07-24 | 2022-06-01 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113667640B (zh) * | 2021-08-27 | 2022-09-02 | 广州百暨基因科技有限公司 | CAR-γδT细胞的制备方法 |
| WO2023102264A1 (en) * | 2021-12-05 | 2023-06-08 | Adicet Therapeutics, Inc. | Treatment of b cell malignancies |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| CN121419987A (zh) * | 2023-07-07 | 2026-01-27 | 南京传奇生物科技有限公司 | 蛋白质及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| AU2005336093B2 (en) | 2004-10-08 | 2011-02-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Adoptive immunotherapy with enhanced T lymphocyte survival |
| JP2008541758A (ja) * | 2005-06-02 | 2008-11-27 | アストラゼネカ エービー | Ｃｄ２０に対する抗体およびその使用 |
| MX2010000970A (es) * | 2007-07-31 | 2010-03-09 | Regeneron Pharma | Anticuerpos humanos contra cd20 humano y metodo para utilizarlos. |
| WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PT2710123T (pt) | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| HK1212240A1 (en) * | 2012-09-07 | 2016-06-10 | 吉宁特有限公司 | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| CN107058354A (zh) * | 2013-04-01 | 2017-08-18 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| EP3060059A4 (en) | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| CN107075480A (zh) | 2014-07-09 | 2017-08-18 | Tc生物制药有限公司 | γδT细胞及其用途 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| EP3189073B2 (en) * | 2014-09-04 | 2025-06-11 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| IL297773B2 (en) * | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| AU2016274633B2 (en) | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| SG11201803934YA (en) | 2015-11-11 | 2018-06-28 | Intrexon Corp | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| US11299708B2 (en) | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| WO2018085690A1 (en) * | 2016-11-04 | 2018-05-11 | Bluebird Bio, Inc. | Anti-bcma car t cell compositions |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| WO2018133877A1 (zh) | 2017-01-23 | 2018-07-26 | 科济生物医药（上海）有限公司 | 靶向bcma的抗体及其应用 |
| SG10202107136XA (en) * | 2017-02-08 | 2021-07-29 | Agency Science Tech & Res | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same |
| GB2562774A (en) | 2017-05-25 | 2018-11-28 | Mcdonald Michael | Genetic construct |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| CA3112584A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
-
2019
- 2019-10-01 US US17/281,574 patent/US20210388100A1/en active Pending
- 2019-10-01 BR BR112021006182-7A patent/BR112021006182A2/pt unknown
- 2019-10-01 CN CN201980070384.5A patent/CN113056283A/zh active Pending
- 2019-10-01 WO PCT/US2019/054132 patent/WO2020072536A1/en not_active Ceased
- 2019-10-01 KR KR1020217012805A patent/KR20210070330A/ko active Pending
- 2019-10-01 MX MX2021003745A patent/MX2021003745A/es unknown
- 2019-10-01 EA EA202190926A patent/EA202190926A1/ru unknown
- 2019-10-01 AU AU2019354391A patent/AU2019354391A1/en active Pending
- 2019-10-01 SG SG11202103235PA patent/SG11202103235PA/en unknown
- 2019-10-01 JP JP2021542089A patent/JP7687952B2/ja active Active
- 2019-10-01 EP EP19795699.8A patent/EP3860645A1/en active Pending
- 2019-10-01 CA CA3115139A patent/CA3115139A1/en active Pending
-
2021
- 2021-03-31 IL IL281922A patent/IL281922A/en unknown
-
2025
- 2025-05-22 JP JP2025085673A patent/JP2025134707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025134707A5 (enExample) | ||
| EP1786837B1 (en) | Antibodies to dkk-1 | |
| JP2022065073A (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| JP2024522357A (ja) | クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 | |
| JP2023139070A5 (enExample) | ||
| WO2019129053A1 (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2022501074A5 (enExample) | ||
| CN107530419A (zh) | 治疗疾病的组合疗法 | |
| WO2017148424A1 (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| JP2013063973A (ja) | 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体 | |
| JP2024531409A5 (enExample) | ||
| WO2002034292A1 (fr) | Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active | |
| CN110114371A (zh) | 嵌合抗原受体 | |
| JP2022542559A5 (enExample) | ||
| JP2022513321A5 (enExample) | ||
| JP2024540275A5 (enExample) | ||
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| WO2021088904A1 (zh) | 抗人程序性死亡配体-1(pd-l1)的抗体及其用途 | |
| JP2025134864A (ja) | 抗ケモカイン様受容体１ヒト化抗体及びその治療適用 | |
| EP3013858A1 (en) | Il-21 binding proteins and uses thereof | |
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| CN114786723A (zh) | 序贯抗cd19疗法 | |
| TWI876192B (zh) | 人類介白素-4受體α抗體 | |
| KR20210060355A (ko) | 항-CD300c 단클론 항체를 포함하는 암 예방 또는 치료용 조성물 | |
| CN111704671B (zh) | Ox40抗体及其在治疗癌症中的应用 |